Observational study on Epithelioid Haemangioendothelioma
Official title: The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets
Run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06680401 · Data updated 2026-11-12
This study is trying to learn more about Epithelioid Haemangioendothelioma, a rare type of cancer, by collecting information on how it behaves and how well different treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Drugs / interventions | bevacizumab, apatinib, chemotherapy |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | February 25, 2021 |
| Main results expected | February 2028 |
| Study ends | December 2028 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT06680401 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a histological diagnosis of EHE as per the 2020 WHO classification, regardless of age.
✕Probably not a fit
Patients unable to ensure adequate compliance with treatment or follow-up may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on Epithelioid Haemangioendothelioma (EHE), a rare vascular soft tissue sarcoma, to gather extensive data on its clinical presentation, natural history, and treatment outcomes. The study aims to identify cytokines and hormones as potential biomarkers and to create patient-derived preclinical models for evaluating anticancer agents and validating new therapeutic targets. By analyzing the genetic translocations associated with EHE, the research seeks to enhance understanding of the disease and improve treatment strategies.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic and therapeutic approaches for patients with EHE.
How similar studies have gone: While EHE is an ultra-rare condition, similar observational studies in rare cancers have shown promise in identifying biomarkers and improving treatment outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen * Signed informed consent * Adequate patient compliance to treatment or follow up * No age limit Exclusion Criteria: * Impossibility to ensure adequate compliance
Where it's running
-
Fondazione IRCCS IstitutoNazionale dei Tumori
Milan, Italy Recruiting
Study contacts
- Principal investigator: Silvia Stacchiotti — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study coordinator: Silvia Stacchiotti
- Email: Silvia.Stacchiotti@istitutotumori.mi.it
- Phone: 0223902803
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exercise program for women with ovarian cancer before surgery
This study tests whether a structured exercise program can help women with advanced ovarian cancer get stronger and recover better before their surgery.
-
Matching tumor and blood gene tests for HPV-negative head and neck cancer
This project will try to see if a simple blood test can show the same tumor gene patterns as tissue samples in people with HPV-negative head and neck cancer.
-
Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma
We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.
-
Immune profile of people with desmoid-type fibromatosis
This project will test whether immune and inflammatory signals in tumors and blood can explain why some people with sporadic desmoid-type fibromatosis get better on their own or after systemic treatment.
-
Multidisciplinary palliative care pathway tailored to frailty for outpatient advanced cancer patients
This study will test whether a structured outpatient palliative care pathway that uses patient-reported symptom scores to tailor care can reduce symptoms and improve care experience for adults with advanced cancer and frailty.
-
Using a patient's oral microbiota to guide radiotherapy for head and neck cancer
We will test whether profiling the oral microbiota before radiotherapy can help predict and reduce side effects and improve treatment response for adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.